Morningstar

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib

Provided by Dow Jones

By Stephen Nakrosis 




  Aclaris Therapeutics said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration. 



  Lichen planus is an autoimmune disorder that can cause rash on the skin and inside the mouth. The drug is designed as a treatment for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris, the company said. Aclaris added it expects to initiate a phased multi-part Phase 2b trial of the treatment in the fourth quarter. 



  The fast-track designation is given to expedite the review of new drugs that target serious conditions and fill an unmet need, according to the FDA. 



  The company's shares closed the day's regular trading session with a 4.25% loss, at $6.09. After the bell, following news of the fast-track designation, shares spiked to around $6.47 before giving up ground and returning to flat about an hour into the late trading session. 





  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com 





  (END) Dow Jones Newswires



  August 06, 2026 17:49 ET (21:49 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
5 Stocks to Sell for Tax-Loss Harvesting 
 
Plus, earnings season kicks off with big banks. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
 
Even short-term muni funds aren’t totally immune from losses. 
 
 
Amy C. Arnott, CFA 
 
 
 
 

			Sponsor Center